<DOC>
	<DOCNO>NCT01392898</DOCNO>
	<brief_summary>Insulin therapy frequently need achieve adequate glycaemic control type 2 diabetes . Although insulin effective treatment modality , often expense significant weight gain . Weight gain obviously undesirable already overweight population , may also deter optimization insulin therapy . Large inter-individual difference exist level weight gain initiation insulin therapy , clear predictive factor prospectively identify thus far . Liraglutide ( Victoza® ) , human glucagon-like peptide-1 ( GLP-1 ) analogue , improve glycaemic control reduces weight . We hypothesize patient show ( excessive ) weight gain introduce insulin therapy , add liraglutide effective reverse body weight preserve glycaemic control .</brief_summary>
	<brief_title>Liraglutide Insulin Therapy Patients With Type 2 Diabetes</brief_title>
	<detailed_description>Patients type 2 diabetes mellitus short-term ( ≤ 12 month ) insulin therapy concomitant document weight gain ≥ 4 % body weight select treat liraglutide 1.8 mg sc q.d . 26 week compare patient receive standard care ( continuation insulin therapy without liraglutide ) open-label , randomize study . After 26 week , patient receive standard care subsequently treat liraglutide 26 week . The group active liraglutide treatment continue additional 26 week . In way patient benefit liraglutide . All subject continue insulin therapy oral hypoglycaemic agent ( SU derivatives metformin allow ) treatment . With respect safety order avoid hypoglycaemic event , total insulin dose decrease 20 % start liraglutide . Within first week start study medication patient perform frequently self-measured capillary blood glucose profile instruct adjust insulin dose necessary . Initially , insulin dose adjust weekly telephone consultation . Thereafter , patient perform blood glucose profile prior every outpatient visit . A liraglutide-insulin titration algorithm use adjust insulin dose . Every 4-6 week patient visit hospital ass body weight , adjust insulin dose check adverse event .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Patients type 2 diabetes mellitus shortterm insulin therapy ( ≤ 12 month ) ; type insulin allow Documented insulinassociated weight gain ≥ 3.0 kg start insulin therapy inclusion Age 1875 year BMI ≥ 25 kg/m2 Stable glycaemic control mirror HbA1c ≥ 6.5 ≤ 8.5 % Inability provide inform consent Type 1 diabetes mellitus , MODY diabetes , LADA diabetes ( presence antiGAD ) Presence medical condition might interfere current study protocol . Inflammatory bowel disease ( e.g . M. Crohn , ulcerative colitis ) Recurrent hypoglycaemic event Diabetic gastroparesis Heart failure ( LVEF ≤ 30 % ) Use TZDs ( glitazones ) , DDPIV ( dipeptidylpeptidaseinhibitor ) Use medication associate impaired glucose metabolism include corticosteroid Pregnancy breastfeeding ( contraception least 3 month inclusion require fertile woman ) Preexisting thyroid disease Liver disease ( aspartate aminotransferase alanine aminotransferase level three time upper limit normal range ) Renal disease ( creatinine &gt; 130 µmol/l MDRDGFR &lt; 30 ml/min/1.73m2 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>liraglutide</keyword>
	<keyword>insulin</keyword>
	<keyword>type 2 diabetes mellitus</keyword>
</DOC>